|
Match
|
Document |
Document Title |
|
|
US20140050739 |
LOCAL COMPLEMENT INHIBITION FOR TREATMENT OF COMPLEMENT-MEDIATED DISORDERS
The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation... |
|
|
US20120101026 |
Compounds For Enzyme Inhibition
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of... |
|
|
US20080124322 |
Activation and inhibition of the immune system
Activation of the immune response by NF-kB inducers, induction of an anergic response by NF-kB inhibitors and the inhibition and activation of immune response by the administration of an activator... |
|
|
US20070149454 |
Controlled Release Delivery System for Nasal Applications and Method of Treatment
This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or... |
|
|
US20070060527 |
Orally administered small peptides synergize statin activity
This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are... |
|
|
US20120302493 |
Cyclic Peptides As G-Protein Coupled Receptor Antagonists
The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred... |
|
|
US20110288011 |
PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF
The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell... |
|
|
US20110015131 |
METHODS FOR PREVENTING AND TREATING ALZHEIMER'S DISEASE (AD)
The present invention relates to methods for preventing Alzheimer's disease (AD) with an Aβ42 mimotope and binds to an antibody specific for DAEFRH (SEQ ID NO: 1) which is a part of the... |
|
|
US20080132450 |
Pharmaceutical composition for suppression of apoptosis and method for delivering the same
The present invention relates to a pharmaceutical composition for treating heart diseases, neurodegenerative diseases, and diseases and conditions caused by apoptosis, which contains a conjugate... |
|
|
US20070287662 |
Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress
An antioxidant compound is disclosed. The compound is characterized by (a) a peptide including at least three amino acid residues of which at least two are cysteine residues, each having a readily... |
|
|
US20070191272 |
Proteinaceous pharmaceuticals and uses thereof
The present invention provides cysteine-containing scaffolds and/or proteins, expression vectors, host cell and display systems harboring and/or expressing such cysteine-containing products. The... |
|
|
US20060276393 |
Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
Provided herein are methods and compositions for treating or preventing neurodegenerative disorders or blood coagulation disorders. Methods may comprise modulating the activity or level of a... |
|
|
US20060154865 |
Conjugates of insulin-like growth factor-1 and poly(ethylene glycol)
A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up... |
|
|
US20060153801 |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
A non-polydispersed mixture of conjugates in which each conjugate in the mixture comprises a drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may... |
|
|
US20060025337 |
Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
Provided herein are methods and compositions for modulating the activity of sirtuin deacetylase protein family members; p53 activity; apoptosis; lifespan and sensitivity to stress of cells and... |
|
|
US20050137142 |
Combinations useful for the treatment of neuronal disorders
The present invention provides a method for the treatment of neuronal disorders, in a mammal such as a human, which method comprises administering an effective, non-toxic and pharmaceutically... |
|
|
US20160376335 |
POLYMERS CONTAINING MULTIVALENT AMYLOID-BETA-BINDING D-PEPTIDES AND THEIR USE
The invention relates to novel multivalent polymeric amyloid-beta-binding substances composed of several interconnected substances which per se already have amyloid-beta-binding properties, and to... |
|
|
US20150174267 |
COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTIC AGENTS
The present invention is directed to conjugates that include a polypeptide capable of crossing the blood-brain barrier or entering one or more cell types attached to a transport vector, i.e., a... |
|
|
US20150174266 |
APROTININ POLYPEPTIDES FOR TRANSPORTING A COMPOUND ACROSS THE BLOOD-BRAIN BARRIER
The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as... |
|
|
US20140086937 |
IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO
Disclosed herein are compositions and methods useful for controlling β-amyloid levels. In particular, the instant invention relates to an antibody that catalyzes hydrolysis of β-amyloid at a... |
|
|
US20140044725 |
ALZHEIMER'S DISEASE TREATMENT METHOD
The invention relates to antibodies which are used in the preparation of a medicament for the treatment of Alzheimer's disease. More specifically, the invention relates to the use of an antibody... |
|
|
US20100331237 |
GAG BINDING PROTEINS
A method is provided for introducing a GAG binding site into a protein comprising the steps: identifying a region in a protein which is not essential for structure maintenanceintroducing at least... |
|
|
US20080096818 |
PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce... |
|
|
US20060241038 |
Therapeutic agent for Abeta related disorders
The present invention provides a pharmaceutical composition comprising at least one member selected from a compound capable of enhancing Aβ37 production, a compound capable of inhibiting Aβ40 and... |
|
|
US20060228371 |
Immunological control of beta-amyloid levels in vivo
An antibody and vectorized antibody, capable of crossing the blood brain barrier, which catalyze hydrolysis of β-amyloid at a predetermined amide linkage are described. The antibody preferentially... |
|
|
US20050181037 |
Cardiolipin compositions their methods of preparation and use
The invention provides new synthetic routes for cardiolipin with different fatty acids and/or alkyl chains with varying chain length and also with or without unsaturation. The reaction schemes can... |
|
|
US20050014697 |
Compositions and methods for modulating S-nitrosoglutathione reductase
Disclosed herein are methods and compositions for modulating the levels and/or activity of S-nitrosoglutathione reductase (GSNOR) in vivo or in vitro. Specifically disclosed are GSNOR deletion... |
|
|
US20160058874 |
CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY
Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system... |
|
|
US20150315237 |
NMDA Receptor Modulators and Uses Thereof
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning,... |
|
|
US20140107037 |
METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM, OR OTHER DISORDERS
The disclosure relates, at least in part, to methods of treating autism in a patient in need thereof by administering an effective amount of a disclosed compound, e.g., a NMDA receptor glycine... |
|
|
US20120101025 |
Compounds For Enzyme Inhibition
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of... |
|
|
US20120039991 |
USE OF APOPTOSIS INHIBITING COMPOUNDS IN DEGENERATIVE NEUROLOGICAL DISORDERS
The invention provides methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain associated with a neurodegenerative diseases... |
|
|
US20110201558 |
Anaplerotic Therapy for Alzheimer's Disease and the Aging Brain
The present invention describes methods and compositions for the treatment of neurodegenerative conditions including Alzheimer's disease (AD) and aging. The present invention discloses an... |
|
|
US20100331236 |
CYCLIC PEPTIDES AS G-PROTEIN COUPLED RECEPTOR ANTAGONISTS
The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred... |
|
|
US20100233095 |
CONFORMATIONALLY DYNAMIC PEPTIDES
Disclosed are novel peptides that are useful, for example, for detecting target proteins having a β-sheet secondary structure which may be associated with a disease, and for diagnosing and... |
|
|
US20080153743 |
METHODS RELATING TO THE TREATMENT OF FIBROSIS
The invention provides α-helix mimetic structures of formula (I) with the definitions of A, B, D, E, G, W, R1 and R2 as set out in the description and a chemical library relating thereto. The... |
|
|
US20080019986 |
Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof
This invention provides a method of inhibiting the binding of a β-sheet fibril to RAGE on the surface of a cell which comprises contacting the cell with a binding inhibiting amount of a compound... |
|
|
US20070254835 |
COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISORDERS
Compositions, kits and methods are provided for treating or preventing neurological disorders associated with aberrant silencing of gene expression by reestablishing the gene expression through... |
|
|
US20060229233 |
Compositions and methods for treating neurological disorders
Compositions useful for treating neurological disorders including neurodegenerative disorders associated with deleterious protein aggregation, aberrant protein folding, such as brain amylogenic... |
|
|
US20060154871 |
Peptides
The amino acid sequence of several peptides present in Colostrinin is disclosed. These peptides are useful, inter alia, in the treatment of disorders of the immune system and the central nervous... |
|
|
US20050043242 |
Method for treating or preventing Alzheimer's disease
Disclosed is a method for treating or preventing Alzheimer's disease by restricting the level of metabolizable carbohydrate in the diet and/or administering to the patient an effective amount of... |
|
|
US20110312878 |
PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS
The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage comprising a pharmacologically active peptide sequence (X) and a... |
|
|
US20110306558 |
PROSAPOSIN AS A NEUROTROPHIC FACTOR
Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is... |
|
|
US20080227719 |
PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce... |
|
|
US20080020018 |
Combination Products
A pharmaceutical formulation comprises a plurality of seamless minicapsules having a diameter of from 0.5 mm to 5 mm, at least some of the minicapsules containing a methyxanthine as one active... |
|
|
US20070082848 |
VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
The present invention relates to VEGF-C or VEGF-D materials and methods for promoting growth and differentiation of neural stem cells and materials and methods for administering said cells to... |
|
|
US20050059591 |
Prevention and treatment of amyloidogenic disease
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce... |
|
|
US20140057834 |
Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells. |
|
|
US20110258713 |
COMPOSITIONS AND METHODS FOR RE-PROGRAMMING CELLS WITHOUT GENETIC MODIFICATION
The present inventions are directed to compositions and methods regarding the reprogramming of biological samples (such as cells) without introducing exogenous genes to the samples. In particular,... |
|
|
US20080096796 |
Peptides That Stimulate Cell Survival and Axon Regeneration
Peptides which consist of or comprise the tetrameric peptide structural unit: Xaa-Xaa-Xaa-Xaa (SEQ.ID.NO.: 1) in which Xaa at position 1 represents Glu or Asp, Xaa at position 2 represents any... |